Pulse Biosciences (PLSE), Why Is Attention Building Around It?
Pulse Biosciences (PLSE) has drawn attention after recent share price strength, with the stock up over the past month and over the past three months. Investors are assessing what the latest moves imply for future expectations.
For context, the current share price of Pulse Biosciences is US$48.10. The stock has logged a 46.69% 30 day share price return and a 94.42% 90 day share price return, while the 1 year total shareholder return of 203.47% and a very large 3 year total shareholder return indicate notable recent momentum.
Scan beyond Pulse Biosciences and compare this surge with a curated list of 18 high quality undiscovered gems that have been quietly building momentum.
For Pulse Biosciences, that sharp upswing could reflect growing confidence in its bioelectric medicine platform, or it could be mainly sentiment chasing recent gains. How does the current valuation line up with the underlying business?
Most Popular Narrative: 50.3% Overvalued
The most followed narrative currently anchors Pulse Biosciences at a fair value of $32, which sits well below the latest close of $48.10 and establishes a relatively demanding starting point for expectations.
Expansion of nsPFA into thyroid indications through the Vybrance system and related studies may depend on reimbursement decisions and clinical guideline inclusion that take longer to develop than current plans. This could limit growth in disposable sales and keep overall earnings reliant on externally funded equity rather than operating cash flow.
Curious what has to happen for that fair value to make sense. The narrative relies on very fast revenue expansion, rising margins and a rich future earnings multiple. The numbers behind those assumptions are anything but conservative.
Result: Fair Value of $32 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear swing factors for Pulse Biosciences, including faster NANOPULSE-AF enrollment and early Vybrance thyroid revenue, that could shift sentiment.
Find out about the key risks to this Pulse Biosciences narrative.
Next Steps
Given the mixed tone around Pulse Biosciences, you may want to review the full picture quickly and decide where you stand in relation to the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Pulse Biosciences?
If Pulse Biosciences has you thinking more broadly about opportunities, use this moment to review other stocks that fit clear, data driven criteria before the next move.
- Target potential value opportunities early by scanning companies that screen well for quality and pricing using the 50 high quality undervalued stocks.
- Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (51 results) that can better handle pressure when conditions change.
- Reduce surprises in your portfolio by focusing on companies highlighted in a 74 resilient stocks with low risk scores before attention shifts their way.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com